You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antiatherogenic Properties of tert-Butylhydroquinone

    SBC: BIOINVENTIONS, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Atherosclerosis is the underlying cause of most cardiovascular disease and considerable evidence supports the role of hypercholesterolemia as a risk factor for this disease. In preliminary work, we found that tertiary-butyl hydroquinone (TBHQ), at a dose lower than approved for human use, was effective in reducing plasma levels of both total cholesterol and tri ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  2. A simple and effective diagnostic test for gastrointestinal bleeding to improve patient outcomes

    SBC: CUMBERLAND PHARMACEUTICALS, INC.            Topic: 300

    DESCRIPTION provided by applicant Problem Lower gastrointestinal bleeding is a significant medical problem in the United States accounting for more than hospital admissions and tens of billions of dollars of healthcare spending annually It is common for bleeding from a single site to stop and restart multiple times The three modalities now used to diagnose and locate gastrointestina ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Assessing Suicide Risk in the ED: Web-based Education

    SBC: CME DEVELOPMENT GROUP, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Since the late 1980's there has been a sharp rise in the number of children and adolescents presenting to emergency departments (EDs) for psychiatric issues. Given that mental health issues account for 1.6% - 5.0% of all pediatric ED visits, and that Emergency Medical System's (EMS) staffs are the first to interact with these youth, the assessment of psychiatri ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  4. Automated, portable, concurrent, WMD detection system

    SBC: Concurrent Analytical, Inc.            Topic: N/A

    DESCRIPTION (provided by applicant): The overall goal of this project is the development of a fully automated, wireless ethernet capable, near realtime, field deployable immunoassay-based analysis system for the concurrent, ultra low-level detection of biowarfare agents in air or water by using innovations in surface enhanced Raman scattering (SERS) and related supporting materials and hardware. A ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  5. Cancer Imaging and Therapy Platform

    SBC: BIOINVISION INC            Topic: 102

    Summary We will create a preclinical quantitative Cancer Imaging and Therapy Platform CITP which will allow one to study cancer biology and optimize pipelines of technologies imaging agents imaging methods targeted nano therapeutics tumor models etc especially for metastatic and invasive cancers Today primary tumor mass es are clinically controlled with surgical drug and radiatio ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Cardiac Interactions of New Adriamycin Analogs and Taxol

    SBC: GEM Pharmaceuticals            Topic: N/A

    DESCRIPTION (provided by applicant): Paclitaxel (Taxol) and doxorubicin (DOX, Adriamycin) are chemotherapeutic drugs used in treatment of metastatic breast cancer. When used individually, they produce a 30-40 percent response rate. When combined, using high doses of DOX (450-550 mg/m2), the response rate is increased to 85-95 percent. This represents a significant improvement in tumor responsivene ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  7. Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome

    SBC: ATHERSYS, INC.            Topic: NIAAA

    DESCRIPTION provided by applicant This is a resubmission of a Phase I Phase II Fast Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome ARDS ARDS is defined as acute onset hypoxemia bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension A novel and exiting possibility is the use of cells as part of the ther ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Combined Intercostal and Diaphragm Pacing

    SBC: SYNAPSE BIOMEDICAL INC            Topic: N/A

    DESCRIPTION (provided by applicant): Diaphragm activation via bilateral electrical stimulation of the phrenic nerves is a useful therapeutic modality providing artificial ventilatory support in ventilator dependent tetraplegic patients. Unfortunately, most patients with ventilator dependent quadriplegia are not candidates for phrenic nerve pacing due to partial or complete phrenic nerve injury. Ba ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Genome-wide Drosophia RNAi Resource

    SBC: OPEN BIOSYSTEMS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Genetics has provided one of the most discerning and powerful approaches to the dissection of biological function and Drosophila has served as a major model organism for such analyses, many of which have been probed processes relevant to human health. Now gene inactivation by RNAi is revolutionizing genetic approaches. By making possible extremely rapid whole g ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
  10. Development of new inhibitors of androgen receptors

    SBC: Cleveland Biolabs, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): This program is aimed at developing a new class of drugs effective against most aggressive and a poorly curable hormone independent form of prostate cancer (CAP). Failure of androgen ablation therapy is rarely associated with the loss of the androgen receptor (AR) signaling by hormone-independent CaP. AR pathway in such tumors remains constitutively active rega ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government